On March 14, 2017, the Daily Journal featured Venable's representation of Dechra Veterinary Products in an exclusive licensing deal with Kane Biotech, Inc. Under the terms of the deal, Kane grants Dechra an exclusive license to market, commercialize and distribute certain oral care and dermatology products in the North American veterinary market. Dechra secured the same exclusive rights with respect to certain products developed in the future that utilize Kane's patented and patent-pending biofilm technology. The deal is viewed as a significant opportunity for Dechra to build market share in strategic segments of the veterinarian market.
The Venable team consisted of Jim Nelson and Cameron Cole, with assistance from Friedemann Thomma on international tax issues.